Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyadic International (DYAI)
NASDAQ:DYAI
RESEARCH TOOLSreports
Holding DYAI?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.04Last Year’s EPS
-$0.08Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 53.51%
|Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive sentiment, with significant revenue increases and successful collaborations outweighing production cost challenges and market limitations for certain products.Company Guidance
In the Q3 2024 earnings call, Dyadic International provided robust guidance highlighting multiple strategic avenues for revenue generation and growth. The company reported a significant increase in quarterly revenue to approximately $1.96 million, driven by $1 million in license revenue from Proliant and a success fee of $425,000 from Inzyme. Dyadic emphasized a dual-track strategy focusing on near-term licensing and product development to capitalize on the $6 billion serum albumin market and the $900 million DNA/RNA enzymes market. The company's collaboration with Proliant aims to launch research-grade recombinant products like human serum albumin and RNase-free DNASE-1, with expected market entry in the first half of 2025. Furthermore, Dyadic's C1 and Dapibus platforms are facilitating advancements in high-demand segments such as cell culture media, valued at over $4.7 billion, and alternative proteins, including animal-free dairy products. The company also underscored its commitment to achieving significant milestones through partnerships with top pharmaceutical companies and ongoing vaccine development projects targeting diseases like bird flu and Mpox. Overall, Dyadic is poised for substantial growth, leveraging its technological platforms to deliver sustained value to investors and partners.Significant Revenue Increase
Revenue for the quarter ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 for the same period a year ago. This was driven by license revenue of $1 million from Proliant and a success fee of $425,000 from Inzyme.
Major Collaborations and Partnerships
Dyadic received $1 million in access and milestone fees from a partnership with Proliant Health & Biologics, with an additional $500,000 expected. They are also collaborating with two of the top 10 pharmaceutical companies and a leading biotech company.
Decreased Loss from Operations
Loss from operations for the third quarter of 2024 decreased to $203,000 compared to $1,720,000 for the same period a year ago, largely due to licensing revenue and milestone fees.
Strong Cash Position
As of September 30, 2024, Dyadic has cash and investment-grade securities of $10 million compared to $7.3 million as of December 31, 2023.
Advancements in Biopharmaceutical Pipeline
Dyadic is actively developing vaccines for infectious diseases and has engaged in over 15 fully funded human health vaccine and antibody projects.
---
DYAI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DYAI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $1.14 | $1.12 | -1.75% |
| Aug 13, 2024 | $1.35 | $1.36 | +0.74% |
| May 14, 2024 | $1.49 | $1.57 | +5.37% |
| Mar 28, 2024 | $1.67 | $1.67 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dyadic International (DYAI) report earnings?
Dyadic International (DYAI) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Dyadic International (DYAI) earnings time?
Dyadic International (DYAI) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DYAI EPS forecast?
DYAI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.04.
---